Literature DB >> 33074583

Cytomorphologic features of NTRK-rearranged thyroid carcinoma.

Kartik Viswanathan1, Ying-Hsia Chu2, William C Faquin1, Peter M Sadow1.   

Abstract

BACKGROUND: NTRK-rearranged thyroid carcinomas (NRTC), though rare, harbor a potential therapeutic target. The cytomorphologic features by fine needle aspiration (FNA) and the utility of preoperative molecular testing for NRTC remain largely uncharacterized. We provide a detailed cytomorphologic analysis of an institutional NRTC cohort with clinical, radiologic, histopathologic, and molecular correlations.
METHODS: Our NRTC FNA cohort included 21 specimens from 19 patients. The mean age and female-to-male ratio were 42 years and 2.2:1, respectively. Predominantly alcohol-stained Papanicolaou smears and liquid-based preparations were reviewed for 14 patients with available materials, and histologic review of subsequent resections was conducted for all 19 patients. Imaging and clinical data were accessed through electronic medical records.
RESULTS: Sonographically, NRTC were hypoechoic (87%), predominantly solid (53%) with limited central vascularity (27%), ill-defined borders (67%), and microcalcifications (67%). Observed cytomorphologic features include mixed architectural patterns (79%), fibrosis (93%), oncocytic and vacuolated cytoplasm (36% and 43%, respectively), and abundant intranuclear pseudoinclusions (14%). Most NRTC FNAs were classified as suspicious for malignancy or malignant (89%). One case classified as atypia of uncertain significance underwent ThyroSeq sequencing where a NTRK1 fusion was identified.
CONCLUSION: Although NRTC did not show a consistent cytomorphologic signature, mixed architectural patterns, prominent fibrosis and distinct cytoplasmic or nuclear features should raise suspicion for NRTC and, when accompanied by negative BRAFV600E by immunohistochemistry on cell block material, aid in selecting cases for molecular testing. This algorithmic approach may help identify potential NRTC, maximizing treatment options for patients, especially in patients for whom treatment planning is complicated.
© 2020 American Cancer Society.

Entities:  

Keywords:  FNA; NTRK; cytomorphology; histology; kinase; thyroid; thyroid cytology

Mesh:

Substances:

Year:  2020        PMID: 33074583      PMCID: PMC8350964          DOI: 10.1002/cncy.22374

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN: 1934-662X            Impact factor:   5.284


  23 in total

1.  Preoperative diagnosis of benign thyroid nodules with indeterminate cytology.

Authors:  Erik K Alexander; Giulia C Kennedy; Zubair W Baloch; Edmund S Cibas; Darya Chudova; James Diggans; Lyssa Friedman; Richard T Kloos; Virginia A LiVolsi; Susan J Mandel; Stephen S Raab; Juan Rosai; David L Steward; P Sean Walsh; Jonathan I Wilde; Martha A Zeiger; Richard B Lanman; Bryan R Haugen
Journal:  N Engl J Med       Date:  2012-06-25       Impact factor: 91.245

2.  Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

Authors:  Alexander Drilon; Theodore W Laetsch; Shivaani Kummar; Steven G DuBois; Ulrik N Lassen; George D Demetri; Michael Nathenson; Robert C Doebele; Anna F Farago; Alberto S Pappo; Brian Turpin; Afshin Dowlati; Marcia S Brose; Leo Mascarenhas; Noah Federman; Jordan Berlin; Wafik S El-Deiry; Christina Baik; John Deeken; Valentina Boni; Ramamoorthy Nagasubramanian; Matthew Taylor; Erin R Rudzinski; Funda Meric-Bernstam; Davendra P S Sohal; Patrick C Ma; Luis E Raez; Jaclyn F Hechtman; Ryma Benayed; Marc Ladanyi; Brian B Tuch; Kevin Ebata; Scott Cruickshank; Nora C Ku; Michael C Cox; Douglas S Hawkins; David S Hong; David M Hyman
Journal:  N Engl J Med       Date:  2018-02-22       Impact factor: 91.245

3.  Thyroid cytology smear slides: An untapped resource for ThyroSeq testing.

Authors:  Marina N Nikiforova; Marcos Lepe; Lindsey A Tolino; Megan E Miller; N Paul Ohori; Abigail I Wald; Michael S Landau; Cihan Kaya; Umberto Malapelle; Claudio Bellevicine; Giancarlo Troncone; Yuri E Nikiforov; Zubair Baloch
Journal:  Cancer Cytopathol       Date:  2020-07-22       Impact factor: 5.284

4.  Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.

Authors:  Robert C Doebele; Alexander Drilon; Luis Paz-Ares; Salvatore Siena; Alice T Shaw; Anna F Farago; Collin M Blakely; Takashi Seto; Byung Chul Cho; Diego Tosi; Benjamin Besse; Sant P Chawla; Lyudmila Bazhenova; John C Krauss; Young Kwang Chae; Minal Barve; Ignacio Garrido-Laguna; Stephen V Liu; Paul Conkling; Thomas John; Marwan Fakih; Darren Sigal; Herbert H Loong; Gary L Buchschacher; Pilar Garrido; Jorge Nieva; Conor Steuer; Tobias R Overbeck; Daniel W Bowles; Elizabeth Fox; Todd Riehl; Edna Chow-Maneval; Brian Simmons; Na Cui; Ann Johnson; Susan Eng; Timothy R Wilson; George D Demetri
Journal:  Lancet Oncol       Date:  2019-12-11       Impact factor: 41.316

5.  Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics.

Authors:  Ryosuke Okamura; Amélie Boichard; Shumei Kato; Jason K Sicklick; Lyudmila Bazhenova; Razelle Kurzrock
Journal:  JCO Precis Oncol       Date:  2018-11-15

Review 6.  Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers.

Authors:  Yu Chen; Ping Chi
Journal:  J Hematol Oncol       Date:  2018-06-07       Impact factor: 17.388

Review 7.  Receptor Tyrosine Kinase-Targeted Cancer Therapy.

Authors:  Toshimitsu Yamaoka; Sojiro Kusumoto; Koichi Ando; Motoi Ohba; Tohru Ohmori
Journal:  Int J Mol Sci       Date:  2018-11-06       Impact factor: 5.923

Review 8.  Testing algorithm for identification of patients with TRK fusion cancer.

Authors:  Frédérique Penault-Llorca; Erin R Rudzinski; Antonia R Sepulveda
Journal:  J Clin Pathol       Date:  2019-05-09       Impact factor: 3.411

Review 9.  The Afirma Xpression Atlas for thyroid nodules and thyroid cancer metastases: Insights to inform clinical decision-making from a fine-needle aspiration sample.

Authors:  Jeffrey F Krane; Edmund S Cibas; Mayumi Endo; Ellen Marqusee; Mimi I Hu; Christian E Nasr; Steven G Waguespack; Lori J Wirth; Richard T Kloos
Journal:  Cancer Cytopathol       Date:  2020-06-16       Impact factor: 5.284

10.  The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.

Authors:  Steven G DuBois; Theodore W Laetsch; Noah Federman; Brian K Turpin; Catherine M Albert; Ramamoorthy Nagasubramanian; Megan E Anderson; Jessica L Davis; Hope E Qamoos; Mark E Reynolds; Scott Cruickshank; Michael C Cox; Douglas S Hawkins; Leo Mascarenhas; Alberto S Pappo
Journal:  Cancer       Date:  2018-09-11       Impact factor: 6.860

View more
  3 in total

1.  Cytomorphologic features of intraductal salivary gland carcinoma: A multi-institutional study of 13 FNA cases with histologic, molecular, and clinical correlations.

Authors:  Kartik Viswanathan; Peter M Sadow; Zahra Maleki; Michiya Nishino; Zubair W Baloch; Todd E Abbott; Rema Rao; William C Faquin
Journal:  Cancer Cytopathol       Date:  2021-10-01       Impact factor: 4.264

2.  Hürthle cell hurdles: Why do tumors derived from this cell type refuse to reveal their secrets and weaknesses?

Authors:  Peter M Sadow
Journal:  Cancer Cytopathol       Date:  2020-10-12       Impact factor: 5.284

Review 3.  Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders.

Authors:  Alexandros Marios Sofias; Federica De Lorenzi; Quim Peña; Armin Azadkhah Shalmani; Mihael Vucur; Jiong-Wei Wang; Fabian Kiessling; Yang Shi; Lorena Consolino; Gert Storm; Twan Lammers
Journal:  Adv Drug Deliv Rev       Date:  2021-06-15       Impact factor: 15.470

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.